Sivem Pharmaceuticals ULC Ranitidine Product Recall (2019-10-17)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
A. Ranitidine 300 mg Tablet;
| Lot or serial number | Brand name | Companies | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|
| K46484, K50204, K46485, K50206, K50590, K50677, K50908, K48440, K48679, K50207, K50594, K50925, K50928, K50932, K50935, K51080 | B. Ranitidine 150 mg Tablet | - Recalling Firm
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
- Marketing Authorization Holder
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
| DIN 02385953 | Tablet | Ranitidine 150 mg |
| K50941, K50624, K50947, K50950 | A. Ranitidine 300 mg Tablet | - Recalling Firm
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
- Marketing Authorization Holder
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
| DIN 02385961 | Tablet | Ranitidine 300 mg |
A. Ranitidine 300 mg Tablet;
B. Ranitidine 150 mg Tablet
Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).
Wholesalers, Healthcare Establishments, Retailers